Ruane, Cunniff & Goldfarb
Sequoia Fund
Sequoia Fund Elevance Health Inc stake
total: 59
Sequoia Fund ELV trades
- Total transactions:
- 11
- New positions:
- 1
- Added:
- 4
- Reduced:
- 6
- Held since:
- 2021 Q1
- Held for:
- 21 quarters
- Latest activity:
- 2025 Q4
According to 2026 Q1 report, Sequoia Fund holds 532,467 Elevance Health Inc (ELV) shares with a market value of roughly $155.88M accounting for 4.80% of the overall portfolio. To date, the estimated cost basis is nearly $365.88 for "buy" trades and estimated average "sell" price is $481.09. Sequoia Fund first purchased ELV in 2021 Q1, initially acquiring 409,924 shares. Since the initial investment in Elevance Health Inc (ELV), Sequoia Fund has made 10 more transactions.
When did Sequoia Fund buy Elevance Health Inc (ELV)?
Sequoia Fund first invested in Elevance Health Inc (ELV) in 2021 Q1 at the reported quarter-end price of $358.95 per share.
What's the cost basis of Sequoia Fund's ELV stake?
The estimated cost basis for Elevance Health Inc (ELV) stake is around $365.88 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $365.88
- Weighted AVG sell price:
- $481.09
Sequoia Fund's historical trades in Elevance Health Inc
11 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2025 Q4
|
5.13%
|
532,467
|
$350.55
|
$186,656,307
|
-0.16% (-851)
|
-0.01%
|
|
2025 Q3
|
4.67%
|
533,318
|
$323.12
|
$172,325,712
|
+27.29% (+114,351)
|
+1%
|
|
2024 Q4
|
4.77%
|
418,967
|
$368.90
|
$154,556,926
|
+25.55% (+85,268)
|
+0.97%
|
|
2023 Q3
|
5.10%
|
333,699
|
$435.42
|
$145,299,219
|
-2.70% (-9,273)
|
-0.14%
|
|
2023 Q2
|
5.12%
|
342,972
|
$444.29
|
$152,379,030
|
+16.00% (+47,310)
|
+0.71%
|
|
2022 Q4
|
5.21%
|
295,662
|
$512.97
|
$151,665,736
|
-11.08% (-36,854)
|
-0.67%
|
|
2022 Q3
|
5.34%
|
332,516
|
$454.24
|
$151,042,068
|
-3.08% (-10,578)
|
-0.15%
|
|
2022 Q2
|
5.15%
|
343,094
|
$482.58
|
$165,570,303
|
-43.17% (-260,573)
|
-3.11%
|
|
2021 Q4
|
5.76%
|
603,667
|
$463.54
|
$279,823,801
|
-6.56% (-42,383)
|
-0.41%
|
|
2021 Q2
|
5.16%
|
646,050
|
$381.80
|
$246,661,890
|
+57.60% (+236,126)
|
+1.89%
|
|
2021 Q1
|
3.19%
|
$358.95
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.